Editorial

Management of Chronic Hepatitis C Virus Infection: Residual Critical Issues after the DAA Revolution

Until a few years ago, double therapy with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) was the miliary stone in the treatment of chronic Hepatitis C Virus (HCV) infection [1,2], then followed by triple therapy with PEG-IFN plus RBV plus a first-generation protease inhibitor (boceprevir or telaprevir) limitedly to genotype [3].

Published 12 Jan, 2018





SHARE THIS ARTICLE


Renowned Editors

MIT, John Hopkins University, Stanford University, University of Michigan...300+

Rapid Peer Review

We assure 20 days rapid peer review process

Open Access

Open Access is the free, immediate, online availability of novel research

High Visibility

Published articles are easy to find on google, google scholar and other databases